Skip to content

In colorectal metastases patients who require liver resection, does a surgeon having knowledge of liver fat measurements influence surgical planning decisions that result in improved patient outcomes.

In colorectal metastases patients who require liver resection, does a surgeon having knowledge of a quantitative measurement of liver fat influence surgical planning decisions that result in improved patient outcomes in comparison to patients where the surgeon had no knowledge of a quantitative measurement of liver fat.

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000567527
Acronym
LSFACT
Enrollment
20
Registered
2015-06-02
Start date
2015-09-03
Completion date
2018-03-27
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of this study is to determine whether an accurate liver fat measurement, when reviewed by a surgeon, leads to changes in surgical approaches and hospital care that result in improved outcomes for colorectal metastases patients who require liver resection. Who is it for? You may be eligible to join this study if you are aged 18 years or above, and have colorectal liver metastases requiring liver resection. Study details All patients enrolled in this safety and tolerability study will have a liver resection and will be assigned by chance to surgery with the surgeon having knowledge of accurate fat liver measurements or to surgery where the surgeon is not aware of the liver fat content prior to starting the surgery. Patient outcomes will then be assessed through medical records. It is hoped that this study will aid in developing strategies that could lead to better survival and health outcomes for colorectal metastases patients after liver resection.

Interventions

Intervention arm – the surgeon will have knowledge of a quantitative measure of liver fat from MRI (HepaFat-Scan)

Sponsors

Resonance Health Ltd
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

colorectal liver metastases requiring liver resection, abdominal MRI with HepaFat-Scan (acquired after enrollment)

Exclusion criteria

contraindications for MRI

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026